Russ Conroy

Combining regorafenib with nivolumab and chemotherapy appears to improve progression free survival at 6 months among those with advanced esophagogastric adenocarcinoma.

Findings from the phase 3 KEYNOTE-A18 trial support the supplemental biologics license application for a pembrolizumab-based regimen as a treatment for patients with newly diagnosed, high-risk, locally advanced cervical cancer.

Adding all-trans retinoic acid to non-intensive chemotherapy appears to produce higher toxicity in elderly unfit patients with acute myeloid leukemia harboring NPM1 mutations.

Data from the phase 3 LITESPARK-005 trial support the supplemental new drug application for belzutifan as a treatment for patients with advanced renal cell carcinoma.

KT-333 is under investigation as a treatment for adult patients with relapsed/refractory lymphomas, leukemias, and solid tumors in a phase 1 clinical trial.

Objective response rate appears to be numerically higher for patients receiving zanubrutinib for relapsed/refractory mantle cell lymphoma in the second-line setting than in later lines of treatment.

Findings from the phase 2 ALYCANTE trial support axicabtagene ciloleucel as a second-line treatment for patients with relapsed/refractory large B-cell lymphoma who are ineligible to undergo a transplant.

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.

Investigators report no differences in progression-free survival among patients with nonseminomatous testicular cancer who received surveillance or adjuvant chemotherapy in a cohort study.

Data from the phase 2 JACKPOT8 PARTB study support the new drug application for golidocitinib as a treatment for relapsed/refractory peripheral T-cell lymphoma in China.

Data from a phase 1/2 trial support the fast track designation for tulmimetostat as a treatment for patients with ARID1A-mutated advanced, recurrent or metastatic endometrial cancer.

Investigators report acceptable morbidity and health-related quality of life with neoadjuvant chemotherapy plus surgery and concomitant chemoradiotherapy in those with cervical cancer.

Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.

Investigators will assess AFM13 in combination with AB-101 as a treatment for those with relapsed or refractory Hodgkin lymphoma in the phase 2 LuminICE-203 trial.

Findings suggest the presence of different genetic pathways that may drive disparities in outcomes between Black and White patients with endometrioid endometrial cancer, according to Kristin Taylor, MD.

Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.

Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.

Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Data from the phase 3 ASCEND trial and a phase 1/2 trial support the National Medical Products Administration’s approval of acalabrutinib in China as a treatment for chronic lymphocytic leukemia.

Patients with dyserythropoiesis appear to have higher PD-L1 expression than those without in a study population of those with myelodysplastic syndromes.

Real-world data suggest that the presence of pelvic lymphadenopathy should not be viewed as a contraindication to trimodality therapy in nonmetastatic clinically node-positive bladder cancer.

The safety profile of tisotumab vedotin-tftv among those with recurrent or metastatic cervical cancer in the phase 3 innovaTV 301 trial appears to be comparable with prior reports of the agent.

Results from a randomized trial suggest that neoadjuvant FOLFOX may be an effective treatment for patients with locally advanced rectal cancer who are suitable to undergo sphincter-sparing surgery.

Findings from a real-world cohort study may support renewed attention to completing molecular genotyping before first-line therapy for patients with metastatic nonsquamous non–small cell lung cancer.

Investigators report no new safety signals with alectinib as a treatment for those with early-stage, ALK-positive non–small cell lung cancer in the phase 3 ALINDA study.

Jonathan Leeman, MD, indicates that the longer-follow is necessary to confirm late toxicities and disease control associated with adaptive radiotherapy in patients with prostate cancer.

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Investigators report that patients with relapsed/refractory myeloma treated with mezigdomide and dexamethasone primarily experienced myelotoxic effects.

Investigators also report an improvement in time to next intervention with vorasidenib compared with placebo among patients with IDH-mutated glioma in the phase 3 INDIGO trial.